Radiopharm Theranostics Limited

RADX · NASDAQ
Analyze with AI
6/30/2025
6/30/2024
6/30/2023
6/30/2022
Market Cap$48,905$34,170$27,033$26,091
- Cash$29,117$18,575$11,699$26,979
+ Debt$0$0$0$0
Enterprise Value$19,788$15,595$15,334-$888
Revenue$3,633$299$292$9
% Growth1,114.3%2.3%3,210.6%
Gross Profit$39$299$292$9
% Margin1.1%100%100%100%
EBITDA-$38,167-$44,084-$31,191-$17,963
% Margin-1,050.4%-14,732.4%-10,668.6%-203,412.5%
Net Income-$38,342-$47,949-$34,611-$30,339
% Margin-1,055.3%-16,024.3%-11,838.6%-343,550.9%
EPS Diluted-5.28-36-33-29.76
% Growth85.3%-9.1%-10.9%
Operating Cash Flow-$36,645-$22,976-$23,202-$9,916
Capital Expenditures$0$0-$1,531-$28,339
Free Cash Flow-$36,645-$22,976-$24,732-$38,254
Radiopharm Theranostics Limited (RADX) Financial Statements & Key Stats | AlphaPilot